Bencomo-Alvarez, Alfonso E.
Rubio, Andres J.
Olivas, Idaly M.
Gonzalez, Mayra A.
Ellwood, Rebecca
Fiol, Carme Ripoll
Eide, Christopher A.
Lara, Joshua J.
Barreto-Vargas, Christian
Jave-Suarez, Luis F.
Nteliopoulos, Georgios
Reid, Alistair G.
Milojkovic, Dragana
Druker, Brian J. http://orcid.org/0000-0001-8331-8206
Apperley, Jane
Khorashad, Jamshid S.
Eiring, Anna M. http://orcid.org/0000-0001-6533-9150
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K22CA216008, R01CA065823)
Consejo Nacional de Ciencia y Tecnología
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Article History
Received: 22 September 2020
Revised: 19 February 2021
Accepted: 23 February 2021
First Online: 12 March 2021
Compliance with ethical standards
:
: BJD’s potential competing interests—SAB: Aileron Therapeutics, Therapy Architects (ALLCRON), Cepheid, Vivid Biosciences, Celgene, RUNX1 Research Program, EnLiven Therapeutics, Gilead Sciences (inactive), Monojul (inactive); SAB and stock: Aptose Biosciences, Blueprint Medicines, Iterion Therapeutics, Third Coast Therapeutics, GRAIL (SAB inactive); scientific founder: MolecularMD (inactive, acquired by ICON); board of directors and stock: Amgen; board of directors: Burroughs Wellcome Fund, CureOne; joint steering committee: Beat AML LLS; founder: VB Therapeutics; clinical trial funding: Novartis, Bristol-Myers Squibb, Pfizer; Royalties from Patent 6958335 (Novartis exclusive license) and OHSU and Dana-Farber Cancer Institute (one Merck exclusive license). The remaining authors have no competing interests.